Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.


The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.

Publication types

  • Review

MeSH terms

  • Antimalarials / therapeutic use*
  • Artemisinins / therapeutic use
  • Asia, Southeastern
  • Drug Resistance, Microbial*
  • Drug Therapy, Combination
  • Humans
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / parasitology
  • Plasmodium falciparum*


  • Antimalarials
  • Artemisinins
  • artemisinine